查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950439

CDK4/6抑制剂市场按应用、药物类别、剂型、通路和最终用户划分，全球预测，2026-2032年

CDK4/6 Inhibitors Market by Indication, Drug Class, Formulation, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

CDK4/6 抑制剂市场预计到 2025 年将达到 142.5 亿美元，到 2026 年将成长到 158 亿美元，到 2032 年将达到 284.5 亿美元，复合年增长率为 10.38%。

关键市场统计数据
基准年 2025 142.5亿美元
预计年份：2026年 158亿美元
预测年份 2032 284.5亿美元
复合年增长率 (%) 10.38%

探讨 CDK4/6 抑制剂在肿瘤学领域的策略崛起，及其对现代治疗路径的临床、监管和相关人员的影响

CDK4/6抑制剂的临床应用已从早期概念验证阶段发展成为荷尔蒙驱动型乳癌治疗的核心支柱，这促使治疗流程、支付方策略和临床路径进行调整。近年来累积的临床证据表明，该类药物在特定患者群体中具有持久疗效，并强调了精准的患者筛选、毒性管理和治疗顺序策略的重要性。因此，临床、商业和政策相关人员在重新评估这些治疗方法如何与内分泌治疗、标靶治疗以及不断发展的生物标记框架相结合。

识别重塑 CDK4/6 抑制剂应用格局的变革性变化，包括新的试验数据、联合用药策略、监管创新和支付方趋势。

多种变革性因素正在重塑 CDK4/6 抑制剂领域，每一种因素都对临床实践和商业化产生影响。高品质的临床试验数据和不断扩展的真实世界证据正在完善这些药物的临床特征，促使临床医生采用更个人化的治疗顺序和联合治疗策略，优先考虑长期疾病控制并兼顾耐受性。同时，能够加速核准和扩展适应症的监管途径也在不断发展，这些途径反映了基于​​生物标誌物的亚组信息，从而影响着药物上市讨论和与支付方的谈判。

评估美国2025年实施的关税对CDK4/6抑制剂供应链、采购成本和全球取得途径的累积影响

2025年美国关税政策的实施，为全球CDK4/6抑制剂的供应和采购环境引入了新的变数，促使相关人员重新评估其采购和分销安排。供应链经理和采购团队面临越来越大的压力，他们需要应对诸如供应商多元化、审查库存政策以及评估关键生产营运的地理位置等挑战。这些决策受到前置作业时间、跨司法管辖区的监管合规性以及确保患者持续获得口服抗癌药物等关键因素的影响。

按适应症、药物类别、通路、最终用户和剂型提取可操作的细分洞察，以指导商业规划。

严谨的細項分析阐明了 CDK4/6 抑制剂的临床需求、商业性机会和营运复杂性之间的交集。适应症细分将荷尔蒙受体阳性、HER2 阴性乳癌和男性乳癌识别为不同的临床队列，其中前者进一步细分为早期和转移性治疗，需要不同的临床方法和实证依据。药物类别细分根据安全性、给药方案和临床定位区分了阿贝西利、Palbociclib和瑞博西尼，这些因素影响处方趋势和支持服务需求。

检验美洲、欧洲、中东和非洲以及亚太地区的区域因素将如何影响 CDK4/6 疗法的可近性、报销方式和临床应用。

区域趋势将对 CDK4/6 疗法的取得、报销和整合到临床路径中的方式产生深远影响。在美洲，医疗保健系统多种多样，从高度标准化的公共项目到复杂的多方付费环境，都要求申办方透过有针对性的证据和定价策略，探索广泛的报销和获取途径。在欧洲、中东和非洲，法规环境和支付环境不均衡，各国决策、区域采购惯例和癌症治疗基础设施的差异，要求制定本地化的市场进入策略和实施计划。在亚太地区，一些都市区的临床应用进展迅速，而其他地区则面临基础设施和经济方面的障碍，因此需要可扩展的患者支持模式和伙伴关係，以扩展诊断能力和依从性支持。

评估领先的 CDK4/6 开发商的竞争定位、产品线差异化、製造策略和商业性策略，以指南伙伴关係的发展。

活跃于 CDK4/6 领域的公司在临床开发、生产规模和市场定位方面展现出不同的策略，影响竞争动态。一些公司专注于差异化的临床项目和适应症拓展，透过投资头对头研究和联合用药研究，打造引人入胜的临床案例。另一些公司则专注于提高生产效率和增强供应链的稳健性，以支援稳定的产品供应和全球分销。商业策略涵盖了从完善的患者支持体系和数位化药物管理工具，到与肿瘤科医生和支付方的深度合作，以将临床试验结果转化为本地临床实践等各个方面。

为产业领导者提供临床合作、供应弹性、证据产生和商业模式的实用建议，以优化 CDK4/6 抑制剂的推广应用

产业领导者应优先考虑一系列切实可行的措施，以共同增强 CDK4/6 领域的临床影响力和商业性韧性。首先，产生与真实临床问题相符的证据，例如治疗顺序、长期耐受性和亚组疗效，将增强临床医生的信心和支付方的认可。其次，投资供应链多元化和透明的库存策略将降低贸易中断带来的风险，并确保患者治疗的连续性。

明确调查方法、资料收集方法、专家检验和分析框架，以支持对 CDK4/6 动态的可靠认识

本报告的研究结合了结构化的原始研究和二手研究，以确保分析的严谨性和实际应用价值。原始研究包括对肿瘤科医生、药房主任、支付方和供应链高管的专家访谈，以收集从业人员对临床应用、分销挑战和报销趋势的观点。二手研究整合了同侪审查文献、监管文件和公共资料，建构了一个全面的证据基础，以补充从业人员的见解。

CDK4/6抑制剂临床进展、进入挑战、竞争动态和未来发展重点策略要点

综合研究结果凸显了几个长期存在的主题：临床差异化驱动处方行为，药物可及性依赖于支付方的协作参与和可操作证据的生成，而运营韧性则保障了患者获得可靠医疗服务。临床数据和联合治疗策略的进步有望改善治疗效果，但也带来了更复杂的治疗决策，并促使支付方对更完善的证据提出更高的要求。同时，从关税到配药方式等供应链和分销因素，都是影响价格谈判和业务连续性的策略变数。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. CDK4/6抑制剂市场（依适应症划分）

  • 荷尔蒙受体阳性、HER2阴性乳癌
    • 早期
    • 转移性
  • 男性乳癌

9. CDK4/6抑制剂市场依药物类别划分

  • 阿贝西利
  • Palbociclib
  • 利博西克利

第十章：CDK4/6抑制剂市场（依剂型划分）

  • 胶囊
  • 口服锭剂

第十一章：CDK4/6抑制剂市场（依分销管道划分）

  • 电子商务
  • 医院药房
    • 住院病人
    • 邮购
  • 零售药房

第十二章：CDK4/6抑制剂市场（依最终用户划分）

  • 医院
  • 肿瘤中心
  • 专科诊所

13. CDK4/6抑制剂市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 CDK4/6抑制剂市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. CDK4/6抑制剂市场（按国家划分）

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国 CDK4/6 抑制剂市场

17. 中国 CDK4/6 抑制剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Astex Pharmaceuticals
  • AstraZeneca plc
  • Bayer AG
  • Beida Pharmaceutical Company
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • G1 Therapeutics
  • Hanmi Pharm
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Nuvation Bio
  • Onconova Therapeutics Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Shanghai Pharmaceutical Group
Product Code: MRR-4F7A6D4FD865

The CDK4/6 Inhibitors Market was valued at USD 14.25 billion in 2025 and is projected to grow to USD 15.80 billion in 2026, with a CAGR of 10.38%, reaching USD 28.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.25 billion
Estimated Year [2026] USD 15.80 billion
Forecast Year [2032] USD 28.45 billion
CAGR (%) 10.38%

Framing the strategic emergence of CDK4/6 inhibitors in oncology with clinical, regulatory, and stakeholder implications for contemporary treatment pathways

The clinical landscape for CDK4/6 inhibitors has matured from early proof-of-concept into a central pillar of hormone-driven breast cancer management, prompting a recalibration of treatment algorithms, payer approaches, and clinical pathways. Recent years have seen accumulated clinical evidence that underscores durable benefit in selected patient populations and has elevated the importance of nuanced patient selection, toxicity management, and sequencing strategies. As a result, stakeholders across clinical, commercial, and policy domains are reassessing how these therapies integrate with endocrine agents, targeted treatments, and evolving biomarker frameworks.

This introductory overview situates CDK4/6 inhibitors within the broader oncology ecosystem by highlighting critical inflection points that matter to decision-makers. Real-world adoption depends not only on efficacy and safety profiles but on operational elements such as prescribing patterns, monitoring infrastructure, and patient support programs. Consequently, the interplay between clinical evidence, health system readiness, and commercial execution will determine the short- and medium-term practical impact of CDK4/6 agents in routine care.

Identifying transformative shifts reshaping CDK4/6 inhibitor adoption including emerging trial data, combination strategies, regulatory innovations and payer shifts

Several transformative forces are reshaping the CDK4/6 inhibitor landscape, each carrying implications for clinical practice and commercialization. High-quality trial data and expanding real-world evidence have refined the clinical profile of these agents, leading clinicians to adopt more tailored sequencing and combination strategies that prioritize long-term disease control while managing tolerability. At the same time, regulatory pathways have evolved to accommodate accelerated approvals and label expansions informed by biomarker-driven subgroups, which in turn influence formulary discussions and payer negotiations.

Parallel to clinical and regulatory shifts, innovation in combination regimens-pairing CDK4/6 inhibitors with endocrine therapies, targeted agents, or novel modalities-has opened new therapeutic possibilities while introducing complexity to treatment algorithms. Payer landscapes are responding by demanding more robust health economics and outcomes evidence to justify coverage and reimbursement. Operationally, manufacturers and health systems are adapting through expanded patient support programs, digital adherence tools, and streamlined diagnostic workflows to address the practical barriers to sustained therapy. Taken together, these dynamics are converging to redefine standard-of-care choices and to create differentiation opportunities for sponsors that can demonstrate clear value propositions across clinical and economic dimensions.

Assessing cumulative consequences of United States tariff measures in 2025 on CDK4/6 inhibitor supply chains, procurement costs, and global access pathways

The introduction of tariff measures in the United States during 2025 introduced new variables into the global CDK4/6 supply and procurement environment, prompting stakeholders to reassess sourcing and distribution arrangements. Supply chain managers and procurement teams faced elevated pressure to diversify suppliers, revisit inventory policies, and evaluate the geographic footprint of key manufacturing steps. These decisions were influenced by lead-time considerations, regulatory compliance across jurisdictions, and the critical need to maintain uninterrupted patient access to oral oncology agents.

Beyond immediate logistics, the tariff environment prompted downstream effects on contracting and pricing negotiations with distributors, hospital systems, and specialty pharmacies. Manufacturers and distributors increasingly prioritized supply resilience and transparency, investing in alternative supply routes and near-shoring where feasible to mitigate exposure. From a clinical access perspective, health systems and oncology centers had to balance budgetary constraints with continuity of care, reinforcing the role of patient assistance programs and collaborative planning between manufacturers and payers. In summary, tariff-driven disruptions underscored the interconnectedness of global manufacturing, regulatory compliance, and patient access strategies, making supply chain agility a strategic imperative.

Distilling actionable segmentation insights across indication, drug class, distribution channel, end user, and formulation to inform commercial planning

A rigorous segmentation lens clarifies where clinical need, commercial opportunity, and operational complexity intersect for CDK4/6 inhibitors. Indication segmentation recognizes hormone receptor positive HER2 negative breast cancer and male breast cancer as distinct clinical cohorts, with the former further differentiated into early stage and metastatic treatment contexts that necessitate varied clinical approaches and evidence bases. Drug class segmentation differentiates Abemaciclib, Palbociclib, and Ribociclib by their individual safety profiles, dosing paradigms, and clinical positioning, which in turn shape prescribing preferences and support service requirements.

Distribution channel considerations span e-commerce, hospital pharmacies, and retail pharmacies, with hospital pharmacies themselves encompassing inpatient and mail order modalities that affect dispensing logistics and adherence supports. End user segmentation highlights the differing operational realities and decision drivers at hospitals, oncology centers, and specialty clinics, where formulary processes, oncology nurse roles, and infusion-adjacent services influence uptake and long-term management. Finally, formulation differentiation between capsules and oral tablets affects packaging, adherence, and patient counseling needs. Taken together, these segmentation dimensions point to targeted strategies: evidence generation tailored to indication and stage, differentiation based on drug-specific clinical characteristics, distribution models optimized for patient access and adherence, and end-user engagement calibrated to institutional workflows and treatment delivery models.

Examining how regional forces in the Americas, EMEA, and Asia-Pacific influence CDK4/6 therapeutic access, reimbursement approaches, and clinical uptake

Regional dynamics exert a profound influence on how CDK4/6 therapies are accessed, reimbursed, and integrated into clinical pathways. In the Americas, health systems vary from highly standardized public programs to complex multi-payer environments, creating a spectrum of reimbursement and access mechanisms that sponsors must navigate through targeted evidence and pricing strategies. Europe, Middle East & Africa present heterogeneous regulatory and payer environments where national decision-making, regional procurement practices, and differing levels of oncology infrastructure require locally adapted market access and launch plans. Asia-Pacific markets display rapid clinical uptake in certain urban centers while facing infrastructure and affordability barriers in other areas, driving a need for scalable patient support models and partnerships that extend diagnostic and adherence capabilities.

Across these regions, differences in diagnostic availability, clinician familiarity with CDK4/6 agents, and the maturity of oral oncology programs shape adoption curves. Reimbursement criteria and health technology assessment approaches also vary markedly, necessitating region-specific health economics evidence and real-world data strategies. Ultimately, successful engagement requires a nuanced appreciation of regional payer frameworks, clinical practice norms, and operational constraints, combined with strategic investments in local evidence generation and provider education to support sustainable uptake.

Evaluating competitive positioning, pipeline differentiation, manufacturing strategies, and commercial tactics among leading CDK4/6 developers to guide partnerships

Companies active in the CDK4/6 space exhibit distinct approaches to clinical development, manufacturing scale, and market positioning that influence competitive dynamics. Some developers emphasize differentiated clinical programs and label expansions, investing in head-to-head or combination studies to create a compelling clinical narrative. Others focus on manufacturing efficiencies and supply chain robustness to ensure consistent product availability and to support global distribution. Commercial tactics range from strong patient support infrastructures and digital adherence tools to deep engagements with oncology clinicians and payers that translate trial outcomes into local practice.

Strategic partnerships and licensing arrangements also play a central role in shaping company trajectories, enabling access to regional distribution networks, diagnostic platforms, and localized expertise. Corporate strategies that align clinical differentiation with operational excellence and proactive payer engagement tend to create stronger positioning, particularly as health systems demand clear evidence of value and predictable supply. For stakeholders evaluating competitive landscapes, it is essential to assess pipeline focus areas, manufacturing resilience, and the depth of commercial and clinical support services that underpin sustained adoption.

Actionable recommendations for industry leaders on clinical engagement, supply resilience, evidence generation, and commercial models to optimize CDK4/6 uptake

Industry leaders should prioritize a set of actionable moves that collectively strengthen clinical impact and commercial resilience in the CDK4/6 domain. First, aligning evidence generation with real-world clinical questions-such as sequencing, long-term tolerability, and subgroup effectiveness-will deepen clinician confidence and payer acceptance. Second, investing in supply chain diversification and transparent inventory strategies will reduce vulnerability to trade disruptions and ensure continuity of treatment for patients.

Third, designing patient-centric support programs that address adherence, toxicity management, and financial navigation will enhance treatment persistence and clinical outcomes. Fourth, proactive payer engagement founded on robust health outcomes evidence and practical cost-of-care frameworks will facilitate reimbursement conversations. Finally, forging collaborative partnerships across diagnostic providers, specialty pharmacies, and clinical networks can accelerate adoption while mitigating operational hurdles. Executing these recommendations with clear timelines and measurable objectives will enable organizations to convert insight into material improvements in patient access and therapeutic value.

Clarifying research methodology, data collection approaches, expert validation, and analytical frameworks that underpin reliable insights on CDK4/6 dynamics

The research underpinning this report integrates structured primary and secondary approaches designed to ensure analytical rigor and practical relevance. Primary research comprised expert interviews with oncologists, pharmacy directors, payers, and supply chain executives to capture practitioner perspectives on clinical use, distribution challenges, and reimbursement dynamics. Secondary research synthesized peer-reviewed literature, regulatory documentation, and public policy sources to construct a comprehensive evidence base that complements practitioner insights.

Analytical frameworks applied in the study include comparative clinical profile assessments, supply chain vulnerability mapping, and stakeholder impact analyses that consider regulatory and payer heterogeneity. Expert validation rounds were conducted to test emerging findings and to refine interpretations. This mixed-methods approach yields balanced, actionable insights by combining quantitative literature-based evidence with qualitative insights from frontline stakeholders, thereby supporting robust conclusions about clinical, operational, and commercial implications for CDK4/6 therapies.

Summarizing strategic takeaways on clinical progress, access challenges, competitive dynamics, and the priorities that will shape the future trajectory of CDK4/6

The consolidated findings emphasize a few persistent themes: clinical differentiation drives prescribing behavior; access depends on coordinated payer engagement and pragmatic evidence generation; and operational resilience underpins reliable patient access. Advances in clinical data and combination strategies have raised expectations for improved outcomes, but they have also increased complexity in treatment decision-making and in the evidence required by payers. Concurrently, supply chain and distribution considerations-from tariffs to dispensing modalities-have become strategic variables that influence both price negotiations and operational continuity.

Looking ahead, stakeholders that integrate robust clinical strategies with resilient supply models, targeted regional approaches, and sophisticated payer engagement will be best positioned to realize the therapeutic and commercial potential of CDK4/6 agents. The priorities that emerge from this synthesis provide a practical roadmap for sponsors, providers, and payers seeking to optimize patient outcomes while navigating an increasingly complex therapeutic environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CDK4/6 Inhibitors Market, by Indication

  • 8.1. Hormone Receptor Positive HER2 Negative Breast Cancer
    • 8.1.1. Early Stage
    • 8.1.2. Metastatic
  • 8.2. Male Breast Cancer

9. CDK4/6 Inhibitors Market, by Drug Class

  • 9.1. Abemaciclib
  • 9.2. Palbociclib
  • 9.3. Ribociclib

10. CDK4/6 Inhibitors Market, by Formulation

  • 10.1. Capsules
  • 10.2. Oral Tablets

11. CDK4/6 Inhibitors Market, by Distribution Channel

  • 11.1. E Commerce
  • 11.2. Hospital Pharmacies
    • 11.2.1. Inpatient
    • 11.2.2. Mail Order
  • 11.3. Retail Pharmacies

12. CDK4/6 Inhibitors Market, by End User

  • 12.1. Hospitals
  • 12.2. Oncology Centers
  • 12.3. Specialty Clinics

13. CDK4/6 Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. CDK4/6 Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. CDK4/6 Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States CDK4/6 Inhibitors Market

17. China CDK4/6 Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Astex Pharmaceuticals
  • 18.7. AstraZeneca plc
  • 18.8. Bayer AG
  • 18.9. Beida Pharmaceutical Company
  • 18.10. Bristol-Myers Squibb Company
  • 18.11. Eli Lilly and Company
  • 18.12. G1 Therapeutics
  • 18.13. Hanmi Pharm
  • 18.14. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 18.15. Merck & Co., Inc.
  • 18.16. Novartis AG
  • 18.17. Nuvation Bio
  • 18.18. Onconova Therapeutics Inc.
  • 18.19. Pfizer Inc.
  • 18.20. Roche Holding AG
  • 18.21. Sanofi S.A.
  • 18.22. Shanghai Pharmaceutical Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CDK4/6 INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CDK4/6 INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY EARLY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY EARLY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY METASTATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY METASTATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY METASTATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MALE BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MALE BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MALE BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ABEMACICLIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ABEMACICLIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ABEMACICLIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY PALBOCICLIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY PALBOCICLIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY PALBOCICLIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RIBOCICLIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RIBOCICLIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RIBOCICLIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY E COMMERCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MAIL ORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MAIL ORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY MAIL ORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GCC CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 137. GCC CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 141. GCC CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. G7 CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 161. G7 CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. G7 CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 165. G7 CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. NATO CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. NATO CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. NATO CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. NATO CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 173. NATO CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CDK4/6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA CDK4/6 INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA CDK4/6 INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)